Clinical Trial

A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

Study acronym: POLO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Because of their prolonged survival, patients with 1p/19q-codeleted low-grade oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration. We make the hypothesis that withholding radiotherapy until tumor progression could reduce the risk of neurocognitive deterioration without impairing overall survival.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-01-07; most recent amendment 2026-01-28.
Status change: Not Yet Recruiting → Recruiting 2021-12-31
Trial Details
NCT Number NCT04702581
Lead Sponsor Hospices Civils de Lyon
Conditions Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion
Enrollment 280 participants
Start Date 2021-12-07
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-29